IMR Press / CEOG / Volume 48 / Issue 1 / DOI: 10.31083/j.ceog.2021.01.2240
Open Access Review
Tenofovir disoproxil fumarate for preventing mother-to-child transmission of hepatitis B: a literature review
Show Less
1 Obstetrics-Gynecology, Filantropia Clinical Hospital, 010082 Bucharest, Romania
2 Intensive Care Department, National Institute for Infectious Diseases “Prof. dr. Matei Balș”, 010082 Bucharest, Romania
3 Department of Nephrology, “Dr. Carol Davila” Clinical Nephrology Hospital, 010082 Bucharest, Romania
4 Department of Gastroneterology, Colentina Hospital, 010082 Bucharest, Romania
5 Carol Davila University of Medicine and Pharmacy Bucharest, 010082 Bucharest, Romania
*Correspondence: (Anca Maria Panaitescu)
Clin. Exp. Obstet. Gynecol. 2021, 48(1), 9–18;
Submitted: 27 July 2020 | Revised: 15 November 2020 | Accepted: 16 November 2020 | Published: 15 February 2021
Copyright: © 2021 The Authors. Published by IMR Press.
This is an open access article under the CC BY 4.0 license (

Infection with the hepatitis B virus (HBV) is one of the leading global public health issues. Over 250 million people worldwide have chronic HBV infection, out of which roughly 65 million are women in their reproductive age. The most common route of passing the infection in areas of high endemicity is by mother-to-child transmission (MTCT). In children the infection may still occur despite adequate immunoprophylaxis, however, antiviral medication, such as Tenofovir disoproxil fumarate (TDF), may be helpful in reducing the risk of MTCT. A literature review was conducted concerning TDF’s role in preventing MTCT and its safety in pregnancy. Studies were identified by researching various databases up to 2020 for variations of the following sentence: “Tenofovir disoproxil fumarate and Lamivudine and Telbivudine and Entecavir and pregnancy and transmission and safety and HBV”. Prenatal and perinatal adequate management of maternal HBV infection is of utmost importance, with focus on prevention of MTCT as the key strategy to reduce the global HBV infection burden. This review discusses the most up-to-date evidence from a multidisciplinary perspective of using TDF to reduce MTCT of HBV infection as well as its safety profile for pregnant women.

Hepatitis B
Mother to child
Fetal infection
Fig. 1.
Back to top